MD&A · 2024
In this section4 topics
Overview of Operations
Overview of Operations
Business Overview
Business Overview: Business Overview: In 2024 and 2023, the Group achieved revenue from medical treatment of 2,032 million Bahtand 1,460 million baht, respectively, reflecting a 39% increase, marking an all-time high in revenue. The net profit for 2024 was 283 million baht, which represents a remarkable 198% increase from 95 million baht in 2023. This growth was driven by higher revenues from both outpatient and inpatient services, resulting in a net profit margin of 14% in 2024.
In 2024, revenue from medical treatment exceeded the Group's target of 1,900 million Baht by 7%. However, the net profit margin was slightly below the target. The primary factor affecting the net profit margin was the lower profit margin from Wattanapat Samui Hospital (WPS) at 5.1%, which is a newly opened hospital (its first full year of revenue). During the low season, the hospital's income did not fully cover its expenses. In contrast, Wattanapat Hospitals Trang and Wattanapat Ao Nang Hospitals achieved profit margins of 17.7% and 17.6%, respectively. However, the management has devised plans to increase revenue during the low season.
The reason why the profit in Q4/2024 is similar to Q3/2024 is because foreigners traveled to Thailand later than in previous years. However, as a result of the delayed arrival of foreign tourists, the number of tourists in Q1/2025 has increased significantly compared to the previous quarter and Q1/2024.
For the business direction in 2025, the Group aims for revenue growth of approximately 15%-20%, driven by the increasing number of foreign patients, a group with high margins, compared to 2024. In addition, the Group has added new medical services for more complex diseases.
Operating Results & Financial Condition
Operating Results & Profitability
Operating results and profitability
Statement of profit and loss
Revenue from medical services
The Company's operating results for the year 2023 showed an increase in revenue from all companies, especially Wattanapat Aonang Co., Ltd. and Wattanapat Samui Co., Ltd., which saw a significant increase in revenue from foreign patients. In addition, the Company also benefited from the expansion of its medical service capabilities, including the expansion of the investment phase to cover the care of diseases related to the elderly and more complex diseases, the expansion of ICU and Intermediate ICU, additional inpatient wards, and a cardiac catheterization laboratory (Cath Lab).
Revenue from outpatient and inpatient services increased by 29 percent and 44 percent, respectively. The proportion of outpatient and inpatient services was 29 percent and 71 percent, respectively.
When divided into Thai and foreign nationals, it was found that Thai revenue increased by 21 percent, while foreign revenue increased by 107 percent, resulting in an increase in the proportion of foreign patients to total revenue from 21 percent in 2022 to 31 percent in 2023.
Cost of medical care
In 2024 and 2023, the company’s medical treatment costs amounted to 1,394 million Baht and 1,094 million Baht, respectively, an increase of 27 percent compared to the same period last year. This increase is in line with the rise in revenue. The main cost drivers include expenses for medicines and medical supplies, salaries and overtime for employees (due to the increase in workforce in line with higher revenue), doctor fees, and depreciation. Additionally, the gross profit margin improved from 25 percent in 2023 to 31 percent in 2024.
However, the Group continues to place importance on cost management and is aware of the environmental impact. The Solar Rooftop Project aims to install solar panels in all companies, which will help reduce electricity costs in the future. Economies of scale from the expansion of the Group's operations will result in greater bargaining power for goods and services. The sharing of personnel and the rotation of personnel within the Group will help save on personnel costs.
Selling and administrative expenses
For 2023 and 2022, the Group's selling and administrative expenses decreased to 13 percent and 15 percent of revenue from medical services, respectively. The lower ratio was due to efficient cost management and the sharing of management personnel across the Group, especially middle to senior management, resulting in economies of scale. However, in 2023, there were extraordinary expenses for preparation for the CAC and SET ESG Rating assessments, as well as expenses from personnel development projects, for which consulting firms were hired for special development.
The selling and administrative expenses were incurred from sales promotion activities and the creation of online public relations to introduce new medical services from hospitals that have recently opened.
Financial costs
For 2023 and 2022, the Group's financial costs from borrowings from financial institutions accounted for 2 percent and 3 percent, respectively. The trend of financial costs is expected to decrease as the Company is able to generate more cash flow, has a greater ability to repay loan installments than contracted, and the trend of interest rates is decreasing. However, the Company needs to reserve cash flow for investment in new projects that have already arisen and projects that will arise in the future.
Income tax expense
The Group's income tax expense increased significantly from the previous year due to the significant increase in profit.
Net profit
The Group's net profit margin for 2023 and 2022 was 14 percent and 6 percent, respectively, due to the growth in revenue from medical services, the addition of specialized services, and efficient cost management, resulting in improved overall performance of the Group.
In 2023, the Group incurred extraordinary expenses in preparation for the CAC and SET ESG Rating assessments in 2024, as well as expenses from personnel development projects across the Group, for which consulting firms were hired for special development.
Statement of financial position
Total assets
As of December 31, 2023 and 2022, the amounts were 2,784.0 million Baht and 2,570.4 million Baht, respectively, an increase of 213.6 million Baht or 8.3 percent. The main reason was the increase in investment in the construction of an inpatient building extension, ICU rooms, a Cath Lab center, and the renovation of leased buildings to support social security. The land deposit for the new hospital project in Phuket (Wattanapapha Phuket Hospital), including systems, medical equipment, etc., is included.
Current assets
As of December 31, 2023 and 2022, the amounts were 337.8 million Baht and 319.2 million Baht, respectively. The ratio of current assets to total assets as of December 31, 2023 and 2022 was 12.1 percent and 12.4 percent, respectively. Current assets increased by 18.6 million baht or 5.8 percent, mainly due to increases in trade receivables, inventories, etc., as the Group's revenue grew significantly. The main current assets in 2023 were cash and cash equivalents, trade receivables, and inventories. Non-current assets
As of December 31, 2023 and 2022, the amounts were 2,446.2 million Baht and 2,251.2 million Baht, respectively, an increase of 195 million Baht or 8.7 percent. The main reason was the investment in the construction of an inpatient building extension, ICU rooms, a Cath Lab center, and the renovation of leased buildings to support social security. The land deposit for the new hospital project in Phuket (Wattanapapha Phuket Hospital), including systems, medical equipment, etc., is included. The main non-current assets in 2023 were land, buildings and equipment, prepaid expenses for the purchase of assets, right-of-use assets, and deferred tax assets.
Total liabilities
As of December 31, 2023 and 2022, the amounts were 1,165.4 million Baht and 1,472.2 million Baht, respectively, a decrease of 306.8 million Baht or 20.8 percent. The decrease in total liabilities was mainly due to loans from financial institutions for investment in fixed assets and working capital of subsidiaries that commenced operations in early 2023 and were able to generate continuous revenue growth in 2024.
Current liabilities
As of December 31, 2023 and 2022, the amounts were 315.8 million Baht and 529.0 million Baht, respectively, a decrease of 213.2 million Baht or 40.3 percent. The decrease in current liabilities was mainly due to short-term loans from financial institutions and long-term loans from financial institutions due within one year, and creditors for construction assets that have been completed and paid for. The main current liabilities as of December 31, 2023 were long-term loans due within one year, trade and other current payables, and accrued corporate income taxes.
Non-current liabilities
As of December 31, 2023 and 2022, the amounts were 849.6 million Baht and 943.2 million Baht, respectively, a decrease of 93.6 million Baht or 9.9 percent. The decrease in non-current liabilities was mainly due to long-term loans from financial institutions, which the Group has gradually repaid. The main liabilities as of December 31, 2023 were long-term loans from financial institutions and estimated employee benefit liabilities.
Shareholders' equity
As of December 31, 2023 and 2022, shareholders' equity amounted to 1,618.7 million Baht and 1,098.2 million Baht, respectively, an increase of 520.5 million Baht or 47.4 percent. The increase in shareholders' equity was mainly attributable to the total comprehensive income for the year 2023 of 278.0 million Baht. Non-controlling interests in subsidiaries increased from investments in subsidiaries of 7.4 million Baht, registered and paid-up capital of 36.6 million Baht, share premium of 270 million Baht, and dividends paid during the year of 72.6 million Baht.
Liquidity & Capital Adequacy
Cash Flow
Net cash flows from operating activities in 2027 Increased from 2026 by 199.16 million Baht, mainly due to higher revenue growth and more efficient debt collection.
Net cash flows used in investing activities in 2027 Mostly used to invest in income-generating fixed assets, including investments in the construction of inpatient building extensions, ICUs, Cath Labs, renovations of leased buildings to support social security, land down payments for the new hospital project in Phuket (Vachira Phuket Hospital), including systems, medical equipment and devices.
Net cash flows used in financing activities in 2027 Mainly from the repayment of long-term loans from financial institutions of 108 million Baht, short-term loans of 197 million Baht, interest expenses of 45 million Baht, and dividend payments of 66 million Baht. Cash flows from financing activities were the receipt of capital increase payments of 300 million Baht.
Liquidity Ratio
As of December 31, 2027, and December 31, 2026, the Company had a current ratio of 1.07 times and 0.60 times, respectively, while the quick ratio was 0.83 times and 0.46 times, respectively. Considering the various liquidity ratios, the Company's liquidity in 2027 increased from the previous year, which stemmed from more efficient working capital management and improved operating results of the group.
Cash Cycle
The Company's average cash cycle in 2027 and 2026 was approximately 22 days and 35 days, respectively. The cash cycle indicates that the Company must prepare cash on hand to support business operations for an average of 22 days. In the past, the Company has mainly used internal cash flow for liquidity management, and the trend of the cash cycle has continuously improved.
Asset Management Capability
Average collection period
The company’s average collection period in 2024 and 2023 was approximately 34 days and 45 days, respectively. The collection period decreased by 11 days due to improved debt collection from insurance clients both domestic and international, as well as from corporate clients, with most remaining within the credit term. Additionally, the company has enhanced its debt collection management capabilities for greater efficiency. However, the Group has already made provisions for expected credit losses in the financial statements.
Return on assets (ROA)
In 2024 and 2023, the return on assets (ROA) was 10.58 percent and 3.97 percent, respectively. The increase in 2023 compared to the previous year is attributed to the company’s improved ability to generate revenue and net profit from its assets, as well as more efficient management of various assets.
Return on equity (ROE)
In 2024 and 2023, the Return on Equity (ROE) was 20.85 percent and 8.87 percent, respectively. In 2023 the second subsidiary commenced operations and generated revenue from on February 18, 2023, which contributed to a continuous increase in revenue. However, the group faced higher costs and expenses from preparations for the opening of the new hospital (Wattanapat Samui Hospital), as well as increased fixed costs, particularly personnel expenses, medical fees, and outsourcing costs. The group also experienced the impact of rising costs, such as electricity, depreciation, interest expenses, goods costs, and personnel expenses. These factors led to a lower ROE for 2023.
Debt Obligations & Off-Balance-Sheet Management
Debt Covenants and Off-Balance Sheet Management
Commitments
As of December 31, 2024, the Company and its subsidiaries had total commitments of THB 1,605.4 million, divided into:
- Capital expenditure commitments totaling THB 428.3 million from the construction of buildings, the purchase of machinery and equipment, and the installation of information systems.
- Lease commitments totaling THB 2.5 million from the lease of land, buildings, and equipment.
- Service agreement commitments totaling THB 30.7 million related to security, medical equipment maintenance, and other services.
- Guarantees totaling THB 1,143.9 million from credit line guarantees provided to subsidiaries and the issuance of guarantees.
Financial Structure Analysis
Key financial ratios of the Group. The information is shown below.
- Debt-to-equity ratio as of December 31, 2024 and 2023 was 0.72 times and 1.34 times, respectively.
- Interest coverage ratio as of December 31, 2024 and 2023 was 11.75 times and 7.04 times, respectively.
Material & Related-Party Transactions
The Company has established procedures for approving related party transactions in accordance with the Securities and Exchange Act and the rules, announcements, orders, or regulations of the Securities and Exchange Commission and the Stock Exchange of Thailand. Directors or persons who may have a conflict of interest, have an interest, or may have a conflict of interest with the Company are not entitled to vote on the approval of such related party transactions. In the event that the law requires that related party transactions must be approved by the Board of Directors meeting, the Company will arrange for the Audit Committee to attend the meeting to consider and provide opinions on the necessity and reasonableness of such transactions, with the following guidelines:
• Transactions with arms-length trading terms: The Board of Directors has approved in principle that management may engage in related party transactions with arms-length trading terms if such transactions have commercial agreements similar to those that would be entered into with other parties in the same circumstances, with bargaining power free from the influence of their status as directors, executives, or connected persons (as the case may be). The company will prepare a report summarizing such transactions for reporting at the Audit Committee and Board of Directors meetings every quarter.
• Ordinary course of business transactions and transactions in support of ordinary course of business which are not on an arm's length basis, and other related party transactions, such as building rental and financial assistance transactions, such as loans, guarantees, etc. The company has a policy to propose to the Board of Directors meeting for approval, with the Audit Committee attending the meeting and providing opinions on the reasonableness and necessity of such transactions before entering into such transactions. The company must comply with the Securities and Exchange Act and the rules, announcements, orders, or regulations of the Stock Exchange of Thailand, including compliance with the regulations on disclosure of connected transactions and the acquisition or disposal of major assets of the company or its subsidiaries (if any), and compliance with the accounting standards on disclosure of information about related parties or related party transactions as prescribed by the Federation of Accounting Professions under the Royal Patronage. The company will disclose related party transactions in the notes to the company's financial statements, including the annual information / annual registration statement (Form 56-1). In addition, in the event that the Audit Committee is required to provide an opinion on the appropriateness of such transactions and the Audit Committee does not have the expertise to consider the related party transactions that occur, the company will arrange for a qualified person, such as an independent auditor or property appraiser, to provide an opinion on the related party transactions. The opinion of the Audit Committee or the qualified person will be used to inform the decision of the Board of Directors or shareholders, as the case may be, to ensure that entering into such transactions will not result in the manipulation or transfer of benefits between the company or persons who may have a conflict of interest with the company, but rather will be transactions that the company has considered in the best interests of all shareholders.
Related party transactions that may occur in the future must be reviewed by the Audit Committee and the Board of Directors, with the Audit Committee attending the meeting to consider and provide opinions on the necessity and reasonableness of such transactions. The review will also include an examination of the pricing and terms of the transactions to ensure they are comparable to those offered to unrelated third parties. Directors must comply with all established regulations and will be restricted from voting to approve any transactions in which they or any potentially conflicted individuals engage with the company. Future related party transactions will continue to be those arising from the company's normal course of business, such as employee dormitory rentals, food service and kitchen space rental agreements, medical services, and the purchase of denture materials. However, the company will conduct these transactions with transparency and in accordance with the company's related party transaction policy, strictly adhering to the regulations of the SEC, the Stock Exchange of Thailand, and other relevant agencies.
Debt Securities with Financial Ratio Requirements
Debt Securities with Financial Ratio Requirements Issued?
No
Factors That May Affect Financial Condition
Factors or Incidents That May Materially Affect Financial Condition
The company assesses factors or events that may significantly impact its financial position or operations. These factors are evaluated and incorporated into operating procedures, key strategies, and the design of continuous monitoring systems to enable the company to manage these risks effectively. This includes appointing a primary responsible committee, assigning primary responsibility to specific departments within the company, etc.
1. Economic Factors
- Interest Rates: Higher interest rates can increase borrowing costs, which affects investments in various hospital projects.
- Inflation: Rising prices for goods and services can increase operating costs, such as medical expenses and medical supplies.
- Economic Climate: If the overall economy is in a recession, service recipients may reduce their use of medical services or purchase less health insurance, which affects hospital revenue.
2. Financial Factors
- Liquidity: Maintaining adequate liquidity is essential for timely payment of liabilities and expenses.
- Debt Management: Increasing debt or extending credit lines can affect financial costs and increase the risk of default.
- Payment Collection: Managing the billing process for patients or insurance companies can affect the hospital's cash flow.
3. Legal and Regulatory Factors
- Health Care Laws: New regulations, such as changes in the health insurance system or price controls for medical treatments, can impact revenue and expenses.
- Financial Reporting Requirements: Changes in financial reporting standards, such as the adoption of IFRS or GAAP for accounting, can affect financial statement reporting.
4. Operational Factors
- Quality of Care: The quality of medical services and treatment affects the hospital's reputation and the number of users.
- Medical Resources Management: Managing medical equipment, supplies, and personnel salaries affects operating costs.
- Patient Flow Management: Managing patient admissions, satisfaction, service experience, as well as queues and bed management, will affect service efficiency.
5. Health Insurance Factors
- Health Insurance Reforms: Changes in health insurance policies, such as changes in insurance company payments or the cancellation of certain types of coverage, can affect revenue from insured patients.
- Negotiations with Insurance Companies: Negotiating service fees with health insurance companies or negotiating prices with insurance providers.
6. Competitive Factors
- Hospital Competition: New hospitals or expansion of services by competitors in the market can affect market share and patient volume. - Expanding Specialized Services: Opening new services or expanding high-demand services, such as surgery or specialized care, can help increase revenue.
7. Technological Factors
- Medical Technology Innovations: Investing in advanced medical technology can increase treatment efficiency and attract patients.
- Healthcare IT Systems: Implementing healthcare information systems, such as Electronic Health Records (EHR), can help manage patient data and reduce costs. Or developing service innovations by using online media to increase work efficiency and increase customer satisfaction.
8. Unexpected Events
- Pandemics: Events such as disease outbreaks can lead to a surge in patients, but they can also increase costs and strain the service system.
- Natural Disasters: These can cause damage to hospital infrastructure and service delivery.
9. Human Resources Factors
- Workforce Management: Having highly skilled and sufficient personnel in various departments will help increase service efficiency and reduce costs.
- Employee Satisfaction: Maintaining employee satisfaction and reducing turnover rates can reduce training and replacement costs.
Projects or R&D Affecting Future Results
In 2024-2025, the company has invested in the following key projects:
1. The project to expand the inpatient bed capacity at Wattanapat Ao-nang Hospital from 59 beds to 90 beds will be operational starting in July 2024.
2. The project to expand the capacity for the treatment of vascular disease patients at Wattanapat Ao Nang Hospital includes the opening of the "Cardiac Catheterization Laboratory" (Cath Lab) and the "Coronary care unit" (CCU). The CCU is a specialized unit for treating patients with critical heart and vascular conditions. All patients within the CCU will have severe heart and vascular-related symptoms in a critical stage. This service began in February 2024.
3. The project to expand the service base for social security beneficiaries includes providing outpatient and inpatient services. This service has been available since January 2025 and is currently ongoing.

